Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

9 Months Ended

Sep. 30, 2021

Note 10 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	September 30,		December 31,
	2021		2020
Accrued clinical and development expenditure	$	13,661	$	13,081
Accrued employee expenses		10,219		11,825
Other accrued expenditure		3,907		2,126
Other		197		47
	$	27,984	$	27,079